LifeCycle Pharma

89 articles about LifeCycle Pharma

• APEIRON EXPANDS EXECUTIVE BOARD AND APPOINTS DR. ANDERSON GAWECO AS CHIEF MEDICAL AND SCIENTIFIC OFFICER (CMSO)

  8/28/2018

  APEIRON Biologics AG, a biotechnology company with a broad preclinical and clinical pipeline and an approved product on the market, focusing on the discovery and development of novel cancer immunotherapies, announced today the appointment of Anderson Gaweco, M.D., Ph.D. as its Chief Medical and Scientific Officer (CMSO).

• LifeCycle Pharma Passing of Extraordinary General Meeting - Change of Company Name to Veloxis Pharmaceuticals A/S and Election of New Board Member

  7/7/2011

• LifeCycle Pharma Drug Works as Well as Rival at Lower Dose; Share Gains

  6/21/2011

• LifeCycle Pharma to Present at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference

  2/11/2011

• LifeCycle Pharma Announces Positive Results of Phase 2 Clinical Trial for LCP-Tacro(TM) in De Novo Liver Transplant Patients

  1/6/2011

• LifeCycle Pharma Announces Positive Results of Phase 2 Clinical Trial for LCP-Tacro in De Novo Liver Transplant Patients

  1/6/2011

• LifeCycle Pharma Announces Completion of Fully Subscribed Equity Offering

  1/6/2011

• LifeCycle Pharma Receives Special Protocol Assessment (SPA) From FDA for LCP-Tacro(TM) Pivotal Phase 3 Study in De Novo Kidney Transplant Patients

  8/12/2010

• LifeCycle Pharma Submits the Phase 3 Protocol for LCP-Tacro(TM) (De No Kidney) to the FDA

  12/23/2009

• LifeCycle Pharma Receives Notice of Allowance for U.S. Patent on Fenoglide(R)

  12/17/2009

• LifeCycle Pharma Promotes Dr. William J. Polvino as New President and Chief Executive Officer

  12/2/2009

• LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro™ Once Daily in Stable Liver Transplant Patients

  9/29/2009

• Jim New Steps Down as CEO of LifeCycle Pharma Today

  8/31/2009

• LifeCycle Pharma Announces First Half 2009 Results, Positive Interim Result for LCP-TacroTM in De Novo Liver Patients and Improves the Full Year Outlook with DKK 100 Million

  8/20/2009

• LifeCycle Pharma's Updated Financial Calendar 2009

  8/13/2009

• LifeCycle Pharma Achieved Strong Progress in its Pipeline

  5/14/2009

• LifeCycle Pharma to Host Conference Call Announcing Interim Report for 1st Quarter 2009 – Results from January 1 to March 31, 2009

  5/11/2009

• LifeCycle Pharma Passing of Annual General Meeting - Subsequent Constitution of the Board of Directors

  4/24/2009

• LifeCycle Pharma: Major Shareholder Announcement

  4/17/2009

• Karin Hamberg Steps Down as Executive Vice President at LifeCycle Pharma

  4/14/2009